

GRS WORKSHOP

Growth Hormone Research Society Perspective on Biomarkers of GH Action in Children and Adults

Aarhus, Denmark, Nov 16-18, 2017

Organizer: Jens Otto Jorgensen

GRS invited 34 international experts including clinicians, basic scientists, a regulatory scientist and physicians from the pharmaceutical industry. The resulting 'statement' from the workshop was submitted for publication in January, 2018. Dr Jorgensen and the writing 'crew' should be commended for their prompt completion of the manuscript.



Conclusions from the workshop:

- The clinical endpoint in pediatric GH treatment is adult height with height velocity as a surrogate endpoint.
- Increased life expectancy is the ideal but unfeasible clinical endpoint of GH treatment in adult GH deficient patients (GHDA) and in patients with acromegaly.
- The pragmatic clinical endpoints in GHDA include normalization of body composition and quality of life, whereas symptom relief and reversal of comorbidities are used in acromegaly.
- Serum IGF-I is widely used as a biomarker, even though it correlates weakly with clinical endpoints in GH treatment.
- In acromegaly, normalization of IGF-I may be related to improvement in mortality.
- There is an unmet need for novel biomarkers that capture the pleiotropic actions of GH in relation to GH treatment and in patients with acromegaly.

UPCOMING EVENTS

Endocrine Society Meeting

Chicago, Ill, March 17-20, 2018

There will be a GRS booth at this meeting.
Please stop by to say hello and bring a friend to join.

European Congress on Endocrinology

Barcelona, Spain, May 10-22, 2018

GRS & IGF Societies 9th International Congress (see below)

9th International Congress of the
Growth Hormone Research
& IGF Societies

September 14-17, 2018



SAVE THE DATE

The Westin Seattle

1900 5th Ave. | Seattle, Washington

grs-igf2018.com

Keynote Speaker: Dr. Leroy Hood

Dr. Hood and his colleagues developed the DNA gene sequencer and synthesizer, and the protein sequencer and synthesizer — instruments that paved the way for successful mapping and understanding of the human genome.


Important Dates:

Abstract deadline:
March 15th

Early registration deadline:
July 13th

Late-breaking Abstracts:
June 15 - July 15th

Seattle, the Emerald City, is an exciting metropolis surrounded by unmatched natural beauty. In addition to its famous landmarks such as the Space Needle, Pike Place Market, Chihuly Garden and Glass, and the Museum of Pop Culture, it is situated between Mount Rainier, the Olympic Peninsula, Puget Sound, and the San Juan Islands, making it a premiere destination for anyone visiting the US.



SUPPORTING MEMBER NEWS

We encourage our Supporting Members to organize a Satellite Session at the upcoming meeting in Seattle. The timing of satellite meetings must not conflict with GRS meeting times. They could occur a day before or after the GRS-IGF Congress or could be held as a breakfast meeting. The host of the Satellite meeting will organize and support the entire event. Speakers for the Satellite meeting must be submitted to GRS-IGF Program Organizing Committee for approval (so as not to conflict with speakers in the Congress).

GRS thanks Supporting Members for your continued and enthusiastic support!



PITUITARY SOCIETY NEWS

THE DAVID L. KLEINBERG EARLY CAREER PITUITARY INVESTIGATOR PRIZES

Awards for the best published peer-reviewed manuscripts devoted to Pituitary Tumor Discovery (print or on-line) Papers must be published during calendar year 2018 (At least one of the three prizes will be awarded to an author published in Pituitary)

1st Place - \$5,000 2nd Place - \$3,000 3rd Place - \$1,000

Prizes will be awarded and presentations will be made at The 16th International Pituitary Congress (Pituitary Congress registration fee, which includes Congress hotel and meal functions will be waived for the three winners).

Eligibility requirements: The winner must be the first author, who is also an Early Career Investigator. Early Career Investigators are defined as those within ten years of completing their terminal research degree or within ten years of completing their medical residency.

How to apply: Submit a re-print of the manuscript and short biography to info@pituitarysociety.org no later than December 31, 2018.

The David L. Kleinberg Memorial Fund was established to memorialize the legacy of David L. Kleinberg. **The fund will support research and educational programs in pituitary disease.**

SAVE THE DATE FOR THESE UPCOMING EVENTS:

Pituitary Society Membership & Career Development Forum
Sunday, March 18, 2018 - Museum of Contemporary Art - Chicago, IL

Updates in Pituitary Diagnosis & Management
Satellite Meeting at International Congress of Endocrinology (ICE)
November 28-30, 2018 - Cape Town, South Africa

16th International Pituitary Congress
March 20-22, 2019 - New Orleans, LA



THE GRS SPONSORED WORKSHOPS ARE ONE OF THE 'KEYSTONES' OF OUR SOCIETY. LISTED BELOW ARE OUR PUBLISHED WORKSHOP STATEMENTS ON ISSUES RELATED TO GH.

13. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016 Jun;174(6): C1-8., 2016. **Pacific Grove, California, USA**
12. Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults. Eur J Endocrinol. 2015 Nov 12. pii: EJE-15-0873. **Manchester, England**
11. Growth Hormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013. Jun;98(6):E1072-87. **Montreal, Canada**
10. Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays.pdf Clin. Chem. 57: 555-559, 2011. **Keswick, Virginia, USA**
9. Statement by the Growth Hormone Research Society on the GH/IGF-I Axis in Extending Health Span. J Gerontol A Biol Sci Med Sci 64A: 1039-1044, 2009. **Reykjavik, Iceland**
8. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 157: 695-700, 2007. **Sydney, Australia**
7. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 93: 4214-4217, 2008. **Santa Monica, California, USA**
6. Management of the Child Born Small for Gestational Age through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 92: 2007. **Manchester, UK**
5. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 152:165-170, 2005. **Manchester, UK**
4. Biochemical Assessment and Long-Term Monitoring in Patients with Acromegaly: Statement from a Joint Consensus Conference of The Growth Hormone Research Society and The Pituitary Society. J Clin Endocrinol Metab 89: 3099-3102, 2004. **Feldafing, Germany**
3. Critical Evaluation of the Safety of Recombinant Human Growth Hormone Administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 86: 1868-1870, 2001. **Keswick, Virginia, USA**
2. Consensus Guidelines for the Diagnosis and Treatment of Growth Hormone (GH) Deficiency in Childhood and Adolescence: Summary Statement of the GH Research Society. J Clin Endocrinol Metab 83: 3990-3993, 2000. **Eilat, Israel**
1. Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 83: 379-381, 1998. **Port Stevens, New South Wales, Australia**